The management of uterine adenomyosis poses challenges, and the prognosis is influenced by:
the range and severity of presenting symptoms, which may vary depending on the depth of lesions[180]Levgur M, Abadi MA, Tucker A. Adenomyosis: symptoms, histology, and pregnancy terminations. Obstet Gynecol. 2000 May;95(5):688-91.
http://www.ncbi.nlm.nih.gov/pubmed/10775730?tool=bestpractice.com
the chosen medical or surgical management, which in turn varies based on the patient's fertility intentions, age, and the presence of co-existing pathologies.[16]Abbott JA. Adenomyosis and abnormal uterine bleeding (AUB-A) - pathogenesis, diagnosis, and management. Best Pract Res Clin Obstet Gynaecol. 2017 Apr;40:68-81.
http://www.ncbi.nlm.nih.gov/pubmed/27810281?tool=bestpractice.com
[86]McElin TW, Bird CC. Adenomyosis of the uterus. Obstet Gynecol Annu. 1974;3(0):425-41.
http://www.ncbi.nlm.nih.gov/pubmed/4608783?tool=bestpractice.com
After menopause, oestrogen deficiency may decrease both symptoms and prevalence of adenomyosis.[12]Templeman C, Marshall SF, Ursin G, et al. Adenomyosis and endometriosis in the California Teachers Study. Fertil Steril. 2008 Aug;90(2):415-24.
https://www.fertstert.org/article/S0015-0282(07)01371-4/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/17919609?tool=bestpractice.com
Recurrence
Recurrence following cessation of medical therapies is almost universal.[181]Wood C. Surgical and medical treatment of adenomyosis. Hum Reprod Update. 1998 Jul-Aug;4(4):323-36.
http://www.ncbi.nlm.nih.gov/pubmed/9825848?tool=bestpractice.com
[182]Vercellini P, Viganò P, Somigliana E, et al. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014 May;10(5):261-75.
http://www.ncbi.nlm.nih.gov/pubmed/24366116?tool=bestpractice.com
The definitive treatment for adenomyosis is a hysterectomy. However, patients opting for certain uterus-sparing surgeries may benefit from preserving their fertility potential, albeit with the risk of recurrence and the possibility of needing further interventions.
One meta-analysis of 42 studies reported an overall symptom recurrence rate of 15.2% after uterine-sparing treatments such as adenomyomectomy, uterine artery embolisation (UAE), and image-guided thermal ablation techniques, with a follow-up period ranging from 6 to 95 months (most studies ≥24 months).[183]Liu L, Tian H, Lin D, et al. Risk of recurrence and reintervention after uterine-sparing interventions for symptomatic adenomyosis: a systematic review and meta-analysis. Obstet Gynecol. 2023 Apr 1;141(4):711-23.
https://journals.lww.com/greenjournal/fulltext/2023/04000/risk_of_recurrence_and_reintervention_after.11.aspx
http://www.ncbi.nlm.nih.gov/pubmed/36897132?tool=bestpractice.com
The reported recurrence rate was 12.6% for adenomyomectomy, 29.5% for UAE, and 10.0% for image-guided thermal ablation (specifically reported after using high-intensity focused ultrasound).[183]Liu L, Tian H, Lin D, et al. Risk of recurrence and reintervention after uterine-sparing interventions for symptomatic adenomyosis: a systematic review and meta-analysis. Obstet Gynecol. 2023 Apr 1;141(4):711-23.
https://journals.lww.com/greenjournal/fulltext/2023/04000/risk_of_recurrence_and_reintervention_after.11.aspx
http://www.ncbi.nlm.nih.gov/pubmed/36897132?tool=bestpractice.com